688
Participants
Start Date
December 31, 2020
Primary Completion Date
March 22, 2023
Study Completion Date
January 26, 2024
Double blind control period A140
experiment arm: Drug A140:400 mg/m2(D1,iv),250 mg/m2(qw,iv) Drug Oxaliplatin 85 mg/m2(D1,iv), Drug Calcium Folinate 400 mg/m2(D1,iv) Drug 5-FU 400 mg/m2(D1,iv),2400 mg/m2 (48±4h) control arm: Drug Erbitux:400 mg/m2(D1,iv),250 mg/m2(qw,iv) Drug Oxaliplatin 85 mg/m2(D1,iv) Drug Calcium Folinate 400 mg/m2(D1,iv) Drug 5-FU 400 mg/m2(D1,iv),2400 mg/m2 (48±4h)
Open single period A140
Drug A140:400 mg/m2(D1,iv),250 mg/m2(qw,iv) Drug Oxaliplatin 85 mg/m2(D1,iv), Drug Calcium Folinate 400 mg/m2(D1,iv) Drug 5-FU 400 mg/m2(D1,iv),2400 mg/m2 (48±4h)
307 Hospital of PLA, Beijing
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
INDUSTRY